REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- Registration Number
- NCT00087646
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This 4 arm study is designed for patients with CHC who have not responded to peginterferon alfa-2b (12KD)/ribavirin combination therapy. In these patients, the effects of lengthening the duration of treatment, as well as including an initial 12-week period of high-dose PEGASYS (360 micrograms sc), are compared with the standard combination therapy of PEGASYS (180 micrograms sc) and ribavirin (1000-1200mg po). The anticipated time on study treatment is 1-2 years and the target sample size is 500+ individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 948
- adult patients >=18 years of age;
- CHC infection;
- liver biopsy (in <24 calendar months of first dose), with results consistent with CHC infection;
- use of 2 forms of contraception during study and 6 months after the study in both men and women;
- Lack of response to previous treatment with peginterferon alfa-2b (12KD)/ribavirin combination therapy given for >=12 weeks.
- women who are pregnant or breastfeeding;
- male partners of women who are pregnant;
- conditions associated with decompensated liver disease;
- other forms of liver disease, including liver cancer;
- human immunodeficiency virus infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Ribavirin - 3 peginterferon alfa-2a [Pegasys] - 2 peginterferon alfa-2a [Pegasys] - 4 peginterferon alfa-2a [Pegasys] - 1 peginterferon alfa-2a [Pegasys] - 4 Ribavirin - 2 Ribavirin - 3 Ribavirin -
- Primary Outcome Measures
Name Time Method Number of Participants With Sustained Virological Response Rate Up to 72 weeks (Group A) and 48 weeks (Group D) Sustained Virological Response (SVR) was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA \< 50 International Units Per Millilitre (IU/mL) measured \>= 20 weeks after treatment end, ie, \>=140 days after treatment end.
- Secondary Outcome Measures
Name Time Method Number of Participants With Sustained Virological Response (Groups A + C vs Groups B + D) At Week 48 and Week 72 SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA \< 50 International Units Per Millilitre (IU/mL) measured \>= 20 weeks after treatment end, ie, \>=140 days after treatment end.
Percentage of Participants With Undetectable HCV-RNA At Week 12, 24, 48 and EOT The percentage of participants with a undetectable HCV RNA 24 weeks after the end of the treatment period (defined as a single last HCV RNA \< 50 IU/mL measured \>= 20 weeks after treatment end, ie, \>=140 days after treatment end) are reported.
End-of-treatment (EOT) virological response is defined as last HCV RNA measurement that is not detectable (\<50 IU/mL) at study day of last dose of study medication (+/- 28 days).Change From Baseline in Reduction of HCV Viremia (Groups A + B vs Groups C + D) At Week 12 and 24 The mean change from baseline in HCV RNA level (reduction in viral load) at Week 12 and 24 were determined. HCV RNA result were not detectable (\<50 IU/ML) and not quantifiable (\<600 IU/ML). Baseline value were assessed on Day 1 before the administration of the first dose of study drug.
Percentage of Participants With Maintenance of Actual End-of-Treatment Virological Response Week 96 (Group A and C) and Week 72 (Group B and D) Maintenance of end-of-treatment virological response was assessed based on all participants treated and according to the actual treatment period (backward imputation method). The percentage of participants who maintained their end-of-treatment virological response was determined. Maintenance of actual end-of-treatment virological response was calculated by dividing the number of participants with a virological response both at the end of the actual untreated follow-up period and at the end of the actual treatment period by the number of participants with a virological response at the actual end of treatment.
Percentage of Participants With >=2log Drop in HCV-RNA At Week 12 and 24 Reduction in HCV-RNA titers of at least 2 log10 after 12/24 weeks of study treatment (i.e. 99% reduction of viral load) was analyzed. Percentage of participants with at least a 2 log10 drop of HCV-RNA at study week 12 and 24 (lower limit of quantitation 600 IU/mL) as compared to baseline or non-detectable HCV-RNA (lower limit of detection 50 IU/mL) were reported.
Percentage of Participants With Relapse After End of Treatment Week 96 (Group A and C) and Week 72 (Group B and D) The percentage of participants who relapsed (loss of response) after having achieved a virological response at the end of treatment was determined.
Number of Participants With Sustained Virological Response (Groups A + B vs Groups C + D) At Week 48 and Week 72 SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA \< 50 International Units Per Millilitre (IU/mL) measured \>= 20 weeks after treatment end, ie, \>=140 days after treatment end.